| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A Kamoun, B Delalleau, M Ozu. [Can a serotonin uptake agonist be an authentic antidepressant? Results of a multicenter, multinational therapeutic trial]. L'Encephale. vol 20. issue 5. 1995-02-23. PMID:7828515. |
the classical biochemical hypothesis of depression posits a functional deficit in central neurotransmitter systems particularly serotonin (5-ht) and noradrenaline. |
1995-02-23 |
2023-08-12 |
mouse |
| A Kamoun, B Delalleau, M Ozu. [Can a serotonin uptake agonist be an authentic antidepressant? Results of a multicenter, multinational therapeutic trial]. L'Encephale. vol 20. issue 5. 1995-02-23. PMID:7828515. |
numerous clinical trials have demonstrated the antidepressant efficacy of such types of serotoninergic agents, supporting 5-ht deficit as the main origin of depression. |
1995-02-23 |
2023-08-12 |
mouse |
| A Kamoun, B Delalleau, M Ozu. [Can a serotonin uptake agonist be an authentic antidepressant? Results of a multicenter, multinational therapeutic trial]. L'Encephale. vol 20. issue 5. 1995-02-23. PMID:7828515. |
therefore, everything seemed clear: depression was caused by 5-ht deficit. |
1995-02-23 |
2023-08-12 |
mouse |
| S B Deshpande, J E Warnic. Thyrotropin-releasing hormone reverses the supersensitively depressed monosynaptic transmission by serotonin in 5,7-dihydroxytryptamine-treated neonatal rats in vitro. Brain research. vol 655. issue 1-2. 1995-02-06. PMID:7812785. |
the depression was about 25% at 10 microm of serotonin, in either control or vehicle-treated groups. |
1995-02-06 |
2023-08-12 |
rat |
| S B Deshpande, J E Warnic. Thyrotropin-releasing hormone reverses the supersensitively depressed monosynaptic transmission by serotonin in 5,7-dihydroxytryptamine-treated neonatal rats in vitro. Brain research. vol 655. issue 1-2. 1995-02-06. PMID:7812785. |
while for the same concentration of serotonin, the depression was 97 +/- 2.1% of the control in cords from 5,7 dihydroxytryptamine (5,7-dht)-treated animals. |
1995-02-06 |
2023-08-12 |
rat |
| C B Montan. Recognition and treatment of depression in a primary care setting. The Journal of clinical psychiatry. vol 55 Suppl. 1995-02-06. PMID:7814355. |
the introduction of the serotonin selective reuptake inhibitors (ssris), antidepressants that are far less toxic and have a milder side effect profile than the tricyclic antidepressants (tcas), has made it possible for depression to be treated more successfully in the primary care setting. |
1995-02-06 |
2023-08-12 |
Not clear |
| T Partone. Involvement of melatonin and serotonin in winter depression. Medical hypotheses. vol 43. issue 3. 1995-02-06. PMID:7815972. |
involvement of melatonin and serotonin in winter depression. |
1995-02-06 |
2023-08-12 |
Not clear |
| P J McGrath, J W Stewart, F M Quitkin, S Wager, S W Jenkins, D G Archibald, J C Stringfellow, D S Robinso. Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. Journal of clinical psychopharmacology. vol 14. issue 5. 1995-02-01. PMID:7806692. |
this is a report of a controlled trial of gepirone, a 5-hydroxytryptamine (5-ht1a) partial agonist azapirone related to buspirone, in the treatment of atypical depression. |
1995-02-01 |
2023-08-12 |
Not clear |
| D E King, D H Finestone, J G Pede. Combination antidepressant therapy in primary care. Archives of family medicine. vol 3. issue 12. 1995-01-31. PMID:7804494. |
increasing clinical experience with the selective serotonin reuptake inhibitors and tricyclic antidepressants make combination antidepressant therapy at times a reasonable alternative to single-agent therapy in primary care patients with depression. |
1995-01-31 |
2023-08-12 |
Not clear |
| P Martin, F Lemonnie. [The role of type 2 serotonin receptors, 5-HT2A and 5-HT2C, in depressive disorders: effect of medifoxamine]. L'Encephale. vol 20. issue 4. 1995-01-12. PMID:7988407. |
the serotonin (5-ht) is implicated in many centrally-regulated functions and has shown to be involved in affective disorders, such as depression and anxiety disorders. |
1995-01-12 |
2023-08-12 |
human |
| E Perucca, G Gatti, E Spin. Clinical pharmacokinetics of fluvoxamine. Clinical pharmacokinetics. vol 27. issue 3. 1995-01-11. PMID:7988100. |
fluvoxamine is a selective inhibitor of serotonin reuptake that is widely used in the management of depression. |
1995-01-11 |
2023-08-12 |
human |
| J M Andrews, C B Nemerof. Contemporary management of depression. The American journal of medicine. vol 97. issue 6A. 1995-01-11. PMID:7992823. |
treatment of depression has improved in recent years because of the availability of effective and well-tolerated antidepressants, such as the selective serotonin reuptake inhibitors (ssris). |
1995-01-11 |
2023-08-12 |
Not clear |
| C D Kilt. Recent pharmacologic advances in antidepressant therapy. The American journal of medicine. vol 97. issue 6A. 1995-01-11. PMID:7992824. |
the serotonergic properties of newer generation antidepressants underscore the role of 5-hydroxytryptamine (5-ht, serotonin) in both the pathophysiology and the pharmacotherapy of major depression. |
1995-01-11 |
2023-08-12 |
Not clear |
| R M Hirschfeld, A F Schatzber. Long-term management of depression. The American journal of medicine. vol 97. issue 6A. 1995-01-11. PMID:7992825. |
the selective serotonin reuptake inhibitors (ssris) have been studied in recurrent depression and are rational choices for initial maintenance therapy because of demonstrated efficacy, safety, and tolerance during long-term therapy. |
1995-01-11 |
2023-08-12 |
Not clear |
| B Levine, A J Jenkins, J E Smiale. Distribution of sertraline in postmortem cases. Journal of analytical toxicology. vol 18. issue 5. 1995-01-06. PMID:7990446. |
sertraline is a potent inhibitor of serotonin reuptake in the central nervous system and is used clinically to treat depression and obsessive-compulsive behavior. |
1995-01-06 |
2023-08-12 |
Not clear |
| D A Sclar, L M Robison, T L Skaer, R F Legg, N L Nemec, R S Galin, T E Hughes, D P Bueschin. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clinical therapeutics. vol 16. issue 4. 1995-01-03. PMID:7982260. |
recent pharmacotherapeutic advances in the treatment of depression have included the development of selective serotonin re-uptake inhibitors (ssris). |
1995-01-03 |
2023-08-12 |
Not clear |
| C V Vorhees, K D Acuff-Smith, M A Schilling, J E Fisher, M S Moran, J Buelke-Sa. A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundamental and applied toxicology : official journal of the Society of Toxicology. vol 23. issue 2. 1994-12-30. PMID:7982528. |
fluoxetine is a widely used serotonin reuptake inhibitor effective in the treatment of depression. |
1994-12-30 |
2023-08-12 |
rat |
| H Crick, N A Manuel, D I Walli. A novel 5-HT receptor or a combination of 5-HT receptor subtypes may mediate depression of a spinal monosynaptic reflex in vitro. Neuropharmacology. vol 33. issue 7. 1994-12-28. PMID:7969810. |
time for peak depression from start of agonist application was 3-4 min for 5-ht, 5 min for sumatriptan and 5-meot, 5-7 min for alpha-me 5-ht and 12 min for 8-oh-dpat. |
1994-12-28 |
2023-08-12 |
rat |
| H Crick, N A Manuel, D I Walli. A novel 5-HT receptor or a combination of 5-HT receptor subtypes may mediate depression of a spinal monosynaptic reflex in vitro. Neuropharmacology. vol 33. issue 7. 1994-12-28. PMID:7969810. |
the half-time for recovery from peak depression was 1.5 +/- 0.3 min for 5-ht, 2.8 +/- 0.3 min for 5-meot, 5.3 +/- 1.5 min for sumatriptan, 13 +/- 2.9 min for 8-oh-dpat and > 30 min for alpha-me 5-ht. |
1994-12-28 |
2023-08-12 |
rat |
| N H Jensen, L Lauritzen, M Lunde, J Eriksen, P Plenge, E T Melleru. Platelet paroxetine binding in depressed and nondepressed chronic pain patients. Acta psychiatrica Scandinavica. vol 90. issue 2. 1994-12-20. PMID:7976461. |
the pain patients who also suffered from depression in addition to the pain had significantly more serotonin transporters than the controls. |
1994-12-20 |
2023-08-12 |
Not clear |